AstraZeneca updates Airsupra U.S. prescribing information

AstraZeneca’s (AZN) Airsupra U.S. prescribing information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma. The BATURA Phase IIIb trial, which evaluated severe exacerbation risk reduction, examined the efficacy of as-needed Airsupra compared to as-needed albuterol, the most commonly used rescue medication for asthma in the U.S. The BATURA trial demonstrated treatment with Airsupra significantly reduced the risk of a severe exacerbation by 46% when compared with albuterol in adult patients with mild asthma.